FDA approves olanzapine, a once-monthly subcutaneous injection for adults with schizophrenia, boosting symptom control while reducing monitoring needs and highlighting weight risks.
News|Articles|October 5, 2012
Treatment Recommendations for Gout: A Summary Table
Author(s)Gregory W. Rutecki, MD
Here: a concise summary of dosing recommendations for the array of pharmacologic options now available to treat gout.
Advertisement
Agents used for gout
Dosing/comments
Allopurinol (long-term uric acid lowering)
Start slowly (50 - 100 mg/d); titrate up to 800 mg/d. Increase dose every 2 - 4 weeks. To reach target uric acid level of 6 mg/dL, start 2 - 4 weeks after acute attack has resolved. Decrease dose in patients with CKD. Exercise caution in patients with CKD4 or worse.
Febuxostat (long-term uric acid lowering)
Daily doses of 80 and 120 mg were, respectively, 2.5 and 3 times more likely to achieve urate levels of < 6 mg/dL as was 300 mg of allopurinol. With creatinine clearances of 30 – 89 ml/min, 80- and 40-mg doses of febuxostat were superior to 200 - 300 mg of allopurinol in lowering uric acid to 6 mg/dL. This is a second-line agent for people who have prohibitive adverse effects with or who fail to respond to allopurinol. Safety data are lacking in patients with advanced CKD.
Colchicine (acute attacks)
Use low-dose regimen: 1.2 mg PO followed once by 0.6 mg PO 1 hour later, then stop.
Corticosteroids (acute attacks)
Prednisone, 40 mg/d for 5 days, especially in patients with CKD4 or worse. May be administered intra-articularly if only 1 or 2 joints are involved.
NSAIDs (acute attacks)
Avoid in patients with renal, hepatic, cardiac failure or with history of GI bleeding; use with caution in the elderly; use with proton pump inhibitor. There are no data for celecoxib efficacy.
Pegloticase
12 biweekly IV infusions for 6 months in patients
Uricosuric drugs (for long-term uric acid lowering)
Author avoids (only effective in under-excreters of uric acid).
Other agents that may affect gout
Do not increase the likelihood of gouty attacks; both losartan and nifedipine may lower uric acid levels.
Low-dose aspirin, cyclosporine, thiazides
Increase likelihood of gouty attacks. Relative risk for gouty attacks with antihypertensives: 0.87, calcium channel blockers; 0.81, losartan; 2.36, diuretics; 1.48, -blockers; 1.24 ACE inhibitors; 1.29, non-losartan ARBs.
References1. Neogi T. Clinical practice. Gout. N Engl J Med. 2011;364:443-452.
2. Laine C, Turner BJ, Williams S, eds. Gout. Annals of Internal Medicine:In the Clinic. 2010;ITC2.
3. Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306:711-720.
4. Choi HK, Soriano LC, Zhang Y, Rodrguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population-based case-control study. BMJ. 2012;344:d8190. doi:10.1136/bmj.d8190.
5. Ruilope LM, Kirwan BA, de Brouwer S, et al; ACTION Investigators. Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome. J Hypertens. 2007;25:1711-1718.
Advertisement
Related to this article
The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication instructions set by their care teams.
FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.
September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Once-Monthly Olanzapine Injection for Adults With Schizophrenia
2
Abbott Gains FDA Approval for CardioMEMS Update Letting Heart Failure Patients View Pressure Readings on Their Phones
3
Multicomponent Strategies to Ease Vaccination Pain and Fear Across Ages
4
FDA Clears IDE for NeuWire Medical's STROKE-REWIRE Trial in Chronic Ischemic Stroke
5